Status:

TERMINATED

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

Lead Sponsor:

Biogen

Conditions:

Multiple Sclerosis

Eligibility:

All Genders

18-85 years

Brief Summary

Phase IV, multi-center, non-treatment, observational, registry study to determine long term effects of AVONEX® therapy on EDSS, MRI, QoL, and cognition.

Detailed Description

The primary objective of this study is to determine the impact of long term AVONEX® treatment on physical status, measured by expanded disability scale score (EDSS), of patients with Multiple Sclerosi...

Eligibility Criteria

Inclusion

  • Patients are eligible to be screened for this study if all of the following criteria are met:
  • All patients must have been originally enrolled in CHAMPS, regardless of randomization arm. Only Cohort 1 patients must have been enrolled in CHAMPIONS 10.
  • Willing and able to provide informed consent (Cohort 1), waiver of informed consent (Cohort 2), or reported patient death through public database search.
  • Ability to read and write English (patient reported assessment tools are in English only).

Exclusion

  • Candidates will be excluded from study screening if any of the following exclusion criteria exist:
  • Patients not participating in the original CHAMPS study.
  • Alternative diagnosis to MS discovered.
  • Patient unwilling or unable to provide informed consent (Cohort 1) or waiver of informed consent (Cohort 2), as applicable.
  • Any other reasons that, in the opinion of the Investigator (Cohort 1) or Patient Coordination Center (Cohort 2), the patient is determined to be unsuitable for enrollment into this study.

Key Trial Info

Start Date :

June 1 2010

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 1 2017

Estimated Enrollment :

383 Patients enrolled

Trial Details

Trial ID

NCT01156298

Start Date

June 1 2010

End Date

March 1 2017

Last Update

August 3 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Research Site

Buffalo, New York, United States, 14203

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance | DecenTrialz